Efficacy as a continuous outcome · patients with cancer and depression
1 finding from 1 review
Efficacy as a dichotomous outcome · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Treatment withdrawal · people with epilepsy and depression
It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).
1 finding from 1 review
RR 0.44 [0.05, 3.85]
15 participants
Very low
Cognitive function · people with epilepsy and depression
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Adverse effects ‐ adverse event profile · people with epilepsy and depression
1 finding from 1 review
Dropout · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Outcomes (2‐6 months post‐treatment) · adults with panic disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
Selective serotonin reuptake inhibitors may leads to lower failure to respond compared with placebo (low certainty).
1 finding from 1 review
Leaving the study early · adults with panic disorder
Selective serotonin reuptake inhibitors showed no clear difference in total number of dropouts compared with placebo (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · adults with panic disorder
Selective serotonin reuptake inhibitors probably leads to lower failure to remit compared with placebo (moderate certainty).
1 finding from 1 review
panic symptoms · adults with panic disorder
2 findings from 1 review